GRI Bio, Inc. has been upgraded to a Zacks Rank #2 (Buy), a rating that reflects an upward trend in earnings estimates. The company is expected to earn -$3.75 per share for the fiscal year ending December 2026, representing no year-over-year change, while over the past three months the Zacks Consensus Estimate for GRI Bio has increased 21.5%. The upgrade places GRI Bio in the top 20% of the more than 4,000 stocks covered by the Zacks Rank system, which assigns only the top 5% a Strong Buy rating and the next 15% a Buy rating. Zacks said the improved earnings outlook could translate into buying pressure and a higher stock price in the near term.
GRI Bio Inc.GRI Bio upgraded to Zacks Rank #2 Buy on a 21.5% rise in consensus earnings estimates over three months.
